利特昔替尼能有效治病吗？

Introduction: The U.S. Food and Drug Administration (FDA) has approved ritexitinib for the treatment of patients 12 years of age and older with severe alopecia areata. Rituxitinib is a once-daily oral treatment that is the first and only FDA-approved treatment for severe alopecia areata in adolescents (12 years and older).

Can the generic version of ritexitinib also effectively treat diseases?

The currently known generic version is produced by Lucius Pharmaceuticals. Its drug ingredients and efficacy are basically the same as the original drug. It has been approved for marketing by relevant departments, so the generic version of ritexitinib can also effectively treat diseases.

Ritexitinib is a JAK inhibitor used to treat alopecia areata. It regulates the immune response in the body and prevents the autoimmune system from attacking hair follicles, thereby slowing or preventing the development of alopecia areata. The generic version of ritexitinib also has basically the same therapeutic effect.

Patients should obtain the generic version of ritexitinib through formal channels to ensure the quality and efficacy of the drug. At the same time, generic drugs can not only reduce the cost of drugs and enable more patients to afford effective treatments, but they also need to ensure that their efficacy and safety are equivalent to those of the original drugs.

The efficacy of ritixitin

The efficacy and safety of ritixitinib were evaluated in the ALLEGRO Phase 2b/3 trial, which enrolled 718 patients with scalp hair loss of 50% or greater as measured by the Severity of Hair Loss Tool (SALT) at 118 sites in 18 countries.

In this pivotal study, 23% of patients treated with ritixitinib 50 mg achieved scalp hair coverage of 80% or greater (SALT ≤ 20) after 6 months, compared with 1.6% of patients treated with placebo. The efficacy and safety of ritixitinib were consistent in adolescents (12-17 years) and adults (18 years and older).

Usage and Dosage of Ritexitinib

The recommended dose of Ritexitinib is 50 mg, taken orally once a day, and can be taken with or without food. Patients need to swallow the capsule whole and do not crush, break or chew the capsule. If you miss a dose, take it as soon as possible, unless it is less than 8 hours before the next dose, in which case the missed dose should be skipped. Thereafter, resume dosing according to your normal dosing schedule.

It should be noted that patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment do not need to adjust the dose, and patients with severe (Child-Pugh Class C) hepatic impairment are not recommended to use ritexitinib.